HBI-2375
HBI-2375 (HYBI-084) is a selective, brain-penetrant and orally active MLL1-WDR5 interaction inhibitor. HBI-2375 inhibits WDR5 with an IC50 of 4.48 nM. HBI-2375 shows inhibition of proliferation in MV4;11 leukemia cells (IC50: 3.17 µM) . HBI-2375 is capable of targeted disruption of histone methyltransferase activity in cancer cells. HBI-2375 can be used for the study of leukemia, glioma and glioblastoma[1][2].
Product Specifications
CAS Number
2982574-79-6
Product Name Alternative
HYBI-084
UNSPSC
12352005
Target
Histone Methyltransferase; WDR5
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Smiles
ClC1=C(C)C(F)=C(N)C=C1C(NC(C=C(N2C=C(C(N3CCN(C)CC3)=O)N=N2)C(F)=C4)=C4N5C[C@@H](C)N(C)[C@@H](C)C5)=O
Molecular Formula
C29H36ClF2N9O2
Molecular Weight
616.11
References & Citations
[1]Farbod Shojaei, et al. Abstract 2640: HBI-2375, a first-in-class IND ready selective MLL1-WDR5 inhibitor, retains desirable preclinical characteristics in solid tumors and in leukemias to be pursued in clinical studies Free. Cancer Res (2024) 84 (6_Supplement) : 2640.|[2]Coker JA, et al. WD repeat domain 5 (WDR5) inhibitors: a patent review (2016-present) . Expert Opin Ther Pat. 2025 Jan;35 (1) :31-45.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K3680702 1.0 µg DNA
Xrcc5 sgRNA CRISPR Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details 